BRAF and cancer: BRAFV600E, which accounts for 90% of BRAF mutations in human cancers [31] and has high catalytic activity alone, does not require dimerization for function [32, 33], which is one of the important reasons for the high degree of malignancy of BRAF-mutant PTC.